According to MBS’ press release, the BBI Group, partner to the world’s leading diagnostic and healthcare organisations, has entered into a definitive agreement to acquire the Maine Biotechnology Services, Inc. (MBS) located in Portland, Maine (USA). The acquisition of MBS will expand BBI’s portfolio during a period of expansion and growth. The company provides a range of products to the diagnostic, healthcare, research food sectors globally. MBS will add antibody development to its capability and product range. Read full story
BBI Group Acquires Maine Biotechnology Services
Related Posts
Bar Harbor approves Jackson Lab’s $33M expansion for rare disease research
The Bar Harbor Planning Board has approved a plan by the Jackson Laboratory to build a 20,000-square-foot expansion to its Rare Disease Translational...
Bigelow lab receives $7 million for algae research, business development
Researchers at Bigelow Laboratory for Ocean Sciences believe algae can make a big splash in the agricultural, aquaculture and pharmaceutical industries,...
Should Maine create a public medical school? UMaine System will study the question
The University of Maine System said this week it will work with a national consultant to study the feasibility of launching the state’s...